What Happened

Immuneel Therapeutics secured over Rs 100 crore ($10.5M) in a Series B funding round. The round was led by Singularity AMC, Rainmatter by Zerodha, and included participation from existing investors like Eight Roads Ventures and F-Prime Capital.

Who Is Affected

The funding impacts Immuneel's operations, enabling expansion of GMP manufacturing and commercialization of Qartemi, India's first approved CAR-T therapy. Investors and regional markets in Asia Pacific and the Middle East will also benefit from increased access to advanced cancer therapies.

Market Impact

• Expands Immuneel's GMP manufacturing capacity.
• Accelerates commercialization of Qartemi for Non-Hodgkin Lymphoma and leukemia.
• Strengthens research and development pipeline.
• Supports regional expansion in Asia Pacific and the Middle East.

What to Watch

Monitor Immuneel's progress in clinical co-development partnerships in Australia and Southeast Asia, as well as its ability to scale Qartemi's adoption in international markets.